Premium
DOUBLE‐BLIND LEVAMISOLE TRIAL IN RESECTABLE LUNG CANCER
Author(s) -
Amery Willem K.
Publication year - 1976
Publication title -
annals of the new york academy of sciences
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.1976.tb41704.x
Subject(s) - levamisole , citation , double blind , annals , lung cancer , medicine , library science , computer science , oncology , history , alternative medicine , classics , pathology , placebo
The third interim analysis of a prospective double-blind placebo-controlled trial with levamisole as an adjunct to surgery in resectable primary lung carcinoma is reported. The data show that a beneficial effect is clearly present in patients who weigh 70 kg or less but not in others; therefore, it would seem advisable to prescribe levamisole at a dosage of 2.5 mg/kg/day. In the adequately dosed patients, an almost complete elimination of distant metastases is found. The levamisole effect also seem more pronounced in patients who have a heavier tumor load at operation. The rationale for starting levamisole before surgery and for continuing thereafter is briefly discussed.